腰椎微创脊柱手术围术期继续抗血小板治疗的临床实践:发病率差异如何?
该队列研究纳入1587例腰椎微创脊柱手术患者,比较围术期继续服用抗血小板药、停药及未用药三组。继续用药组住院时间更长(2.5±0.67天 vs 1.59±0.76天和1.67±0.83天,P<0.05),但手术时间、估计失血量、输血量及总体并发症率无显著差异,无硬膜外血肿相关表现。
要点
- 继续抗血小板治疗组住院时间显著长于停药组和未用药组(P<0.05)。
- 手术时间、估计失血量、输血量及总体并发症率三组间无显著差异。
- 研究组均未出现提示脊柱硬膜外血肿的伤口渗液或神经功能缺损。
核心结论
- 腰椎微创脊柱手术围术期继续服用抗血小板药未明显增加出血相关并发症等围术期发病率。
研究设计与样本
- 回顾性队列研究,经机构审查委员会批准,纳入2011至2018年1587例患者。
- 216例术前停用抗凝治疗、240例围术期每日继续服用抗血小板药、1131例从未暴露于抗血小板治疗。
主要发现
- 继续用药组平均住院时间2.5±0.67天,停药组1.59±0.76天,未用药组1.67±0.83天,P<0.05。
- 手术时间、估计失血量、输血量及总体术中术后并发症率三组间无显著差异。
- 两个研究组均无术后伤口渗液或提示可能脊柱硬膜外血肿的神经功能缺损。
关键数值与推荐
- 继续用药组平均住院时间2.5±0.67天,停药组1.59±0.76天,未用药组1.67±0.83天,P<0.05。
临床怎么用
- 腰椎微创脊柱手术围术期可考虑继续抗血小板治疗,但需注意住院时间可能延长。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Cohort. OBJECTIVE: To evaluate perioperative morbidity in patients undergoing minimally invasive spine surgery of the lumbar spine while continuing the antiplatelet drug (APD) perioperatively as compared with those not continuing these drugs and those not on these drugs. SUMMARY OF BACKGROUND DATA: While discontinuation of antiplatelet drugs carries with it the risk of thrombosis of the cardiac stents, myocardial infarction, peripheral vascular occlusion, cerebro-vascular events and other thrombotic complications, continuation of these drugs has the risk of intra spinal bleeding and the serious consequences of subsequent epidural hematoma with associated spinal cord compression. METHODS: This institutional review board approved study included 1587 patients from 2011 to 2018. Perioperative parameters were analyzed for 216 patients who underwent spinal surgery after the discontinuation of anticoagulation therapy, 240 patients who continued to take APD daily through the perioperative period and 1131 patients who were never exposed to APD therapy. The operative time, intraoperative estimated blood loss, length of hospital stay, incidence of clinically evident hematoma, and transfusion of blood products were also recorded and compared in three cohorts. RESULTS: The patients who continued taking APD in the perioperative period had a longer length of hospital stay on average (2.5 ± 0.67 vs. 1.59 ± 0.76 and 1.67 ± 0.83, P < 0.05), whereas there was no significant difference in the operative time, estimated blood loss, the amount of blood products transfused, and overall intra and postoperative complication rate. There were no instances of postoperative wound soakage or neurological deficit suggestive of possible spinal epidural hematomas in either of the study groups. CONCLUSION: The current study has observed no appreciable increase in perioperative morbidities including bleeding related complication rates in patients undergoing lumbar minimally invasive spine surgery while continuing to take APD compared with patients who either discontinued APD prior to surgery or those not taking APD. LEVEL OF EVIDENCE: 4.
引用
- Kulkarni AG, Patel J, Khandge A, et al. The Practice of Continuation of Anti-platelet Therapy During the Perioperative Period in Lumbar Minimally Invasive Spine Surgery (MISS): How Different Is the Morbidity in This Scenario? Spine (Phila Pa 1976). 2020. PMID: 32358305. doi:10.1097/BRS.0000000000003357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。